Outcomes of Unmanipulated Haploidentical Transplantation Using Post-Transplant Cyclophosphamide (PT-Cy) in Pediatric Patients With Acute Lymphoblastic Leukemia by Ruggeri, Annalisa et al.
Transplantation and Cellular Therapy 27 (2021) 424.e1424.e9
Transplantation and
Cellular Therapy
journal homepage: www.tct journal .orgFull Length Article
PediatricOutcomes of Unmanipulated Haploidentical Transplantation Using
Post-Transplant Cyclophosphamide (PT-Cy) in Pediatric Patients With
Acute Lymphoblastic LeukemiaAnnalisa Ruggeri1,2,*, Jacques-Emmanuel Galimard3, Olesya Paina4, Franca Fagioli5,
Abdelghani Tbakhi6, Akif Yesilipek7, Jose Maria Fernandez Navarro8, Maura Faraci9,
Rose-Marie Hamladji10, Elena Skorobogatova11, Amal Al-Seraihy12, Mikael Sundin13,
Concepcion Herrera14, Jose Rifon15, Arnaud Dalissier3, Franco Locatelli16, Vanderson Rocha17,
Selim Corbacioglu18
1 Department of Hematology and Bone marrow Transplantation, IRCCS San Raffaele Scientific Institute, Milano, Italy
2 Cellular Therapy and Immunobiology Working Party, Leiden, The Netherlands
3 EBMT Paediatric Diseases Working Party, Paris, France
4 First State Pavlov Medical University of St. Petersburg Raisa Gorbacheva Memorial Research Institute for Paediatric Oncology, Hematology and Transplantation, St.
Petersburg, Russia
5 Onco-Ematologia Pediatrica, Centro Trapianti Cellule Staminali, Ospedale Infantile Regina Margherita, Torino, Italy
6 King Hussein Cancer Centre, Amman, Jordan
7Medicalpark Antalya Hospital, Antalya, Turkey
8Hospital Universitario La Fe Servicio de Hematologia Bulevar Sur S/N Valencia, Valencia, Spain
9 Institute G. Gaslini, Genova, Italy
10 Centre Pierre et Marie Curie Alger, Algerie
11 The Russian Childrens Research Hospital, Department of Bone Marrow Transplantation, Moscow, Russia
12 King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
13 Pediatric Hematology, Immunology and HCT Section, Astrid Lindgren Children’s Hospital, Karolinska University Hospital and Division of Pedatrics, CLINTEC, Karolinska
Institutet; Stockholm, Sweden.
14Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Department of Hematology Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain
15 Clínica Universitaria de Navarra Area de Terapia Celular Pamplona, Pamplona, Spain
16 Department of Pediatric Hematology and Oncology, IRCCS Ospedale Pediatrico Bambino Gesu, Rome, Italy
17 Service of Hematology, Transfusion and Cell Therapy and Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology,
HCFMUSP, University of S~ao Paulo Medical School, S~ao Paulo, Brazil
18 Pediatric Hematology, Oncology and Stem Cell Transplantation Department, University of Regensburg, Regensburg, GermanyArticle history:
Received 3 July 2020
Accepted 18 January 2021Financial disclosure: See Acknowled
*Correspondence and reprint requ
Olgettina 58, Milano, Italy.
E-mail address: annalisaruggeri8
https://doi.org/10.1016/j.jtct.2021.01
2666-6367/© 2021 The American SoA B S T R A C T
HLA-haploidentical transplantation (haplo-HCT) using post-transplantation-cyclophosphamide (PT-Cy) is a
feasible procedure in children with malignancies. However, large studies on Haplo-HCT with PT-Cy for child-
hood acute lymphoblastic leukemia (ALL) are lacking. We analyzed haplo-HCT outcomes in 180 children
with ALL. Median age was 9 years, and median follow-up was 2.7 years. Disease status was CR1 for 24%, CR2
for 45%, CR+3 for 12%, and active disease for 19%. All patients received PT-Cy day +3 and +4. Bone marrow
(BM) was the stem cell source in 115 patients (64%). Cumulative incidence of 42-day engraftment was 88.9%.
Cumulative incidence of day-100 acute graft-versus-host disease (GVHD) grade II-IV was 28%, and 2-year
chronic GVHD was 21.9%. At 2 years, cumulative incidence of nonrelapse mortality (NRM) was 19.6%. Cumu-
lative incidence was 41.9% for relapse and 25% for patients in CR1. Estimated 2-year leukemia free survival
was 65%, 44%, and 18.8% for patients transplanted in CR1, CR2, CR3+ and 3% at 1 year for active disease. In
multivariable analysis for patients in CR1 and CR2, disease status (CR2 [hazard ratio {HR} = 2.19; P = .04]),
age at HCT older than 13 (HR = 2.07; P = .03) and use of peripheral blood stem cell (PBSC) (HR = 1.98;
P = .04) were independent factors associated with decreased overall survival. Use of PBSC was also associated
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BM cells as a graft source is associated with improved survival.
© 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights
reserved.In the last 10 years, the number of patients with hemato-
logical malignancies such as acute leukemias transplanted
using haploidentical donors has dramatically increased world-
wide [1]. To avoid the risk of graft-versus-host disease (GVHD)
in cases of HLA-mismatched transplantation, the use of CD34+
selected grafts after ex vivo T-cell depletion was adopted, but
with an excess of graft failure, delayed immune reconstitution,
and increased relapse rate.
In another approach, unmanipulated haploidentical grafts
with in vivo T-cell-depletion with post-transplantation cyclo-
phosphamide (PT-Cy) [2] helped, to some extent, to overcome
the drawbacks of the previous procedure. Unmanipulated HLA-
haploidentical donor transplants (haplo-HCT) with PT-Cy added
to standard immunosuppressive agents, to overcome HLA mis-
matches was first adopted in the adult setting with a reduced-
intensity conditioning regimen (RIC) and using bone marrow
(BM) as a stem cell source andwas associated with low incidence
of GVHD and graft rejection. Despite its mechanism of action in
preventing GVHD not being completely clear, PT-Cy given after
graft infusion is able to abrogate the rapidly proliferating allor-
eactive T-cells in both directions, while preserving hematopoietic
stem cells and the slowly dividing memory and regulatory T-
cells, because of their high content in aldehyde dehydrogenase
[3]. To overcome the excess of relapse reported in adults after
RIC haplo-HCT, some authors effectively reported the application
of BM and PT-Cy with myeloablative regimens (MAC) or with
peripheral blood stem cell (PBSC); however, the last with an
increased risk of acute GVHD [4].
HCT is indicated in children with acute lymphoblastic
leukemia (ALL) namely in cases of persistence of high mini-
mal residual disease level at the end of consolidation ther-
apy with a high-risk cytogenetic feature or in patients in
second complete remission (CR2) according to the timing
and the site of disease relapse [5].
To date, few cases of haplo-HCT using PT-Cy in pediatric
patients with hematologic malignancies were reported by sin-
gle center and registry studies, and fewer than 20 patients
with ALL were analyzed. Therefore the role of haplo-HCT using
PT-Cy for children with ALL is not well established [6,7].
This retrospective and multicenter study on behalf of the
Pediatric Disease Working Party (PDWP) of the European Society
for Blood and Marrow Transplantation (EBMT) aimed to report
the outcomes of pediatric ALL given a non-T-celldepleted
haplo-HCT with PT-Cy. Furthermore, for patients in CR1 and CR2,
we performed a risk factors analysis for main HCT outcomes.
METHODS
Patients and Donors
Data were obtained from the PDWP registry of the EBMT. The EBMT is
a voluntary working group with participating centers required to report
consecutive transplants. Patients were followed up longitudinally. Data
were collected on standardized reporting forms and is subject to audits.
The Institutional Review Board of the PDWP approved this study. Accord-
ing to EBMT rules, patients or legal guardians provided written informed
consent for data collection and use for analysis in accordance with the
Declaration of Helsinki. Included are patients aged up to 18 years, with
ALL in all disease status at HCT (CR1, CR2, and CR3 or more [CR3+] and
active diseases) having received a first allogeneic HCT from 1 January
2011 to 30 June 2019. The graft source was bone marrow or peripheral
blood from parents or other relatives mismatched at least at 2 or more
HLA loci. Patients received a myeloablative or reduced-intensity condi-
tioning regimen according to the transplant center policy. GVHDprophylaxis included PT-Cy, in combination with calcineurin inhibitors,
mycophenolate mofetil or methotrexate according to institutional proto-
cols. Patients with a prior allogeneic transplant (autologous HCT allowed)
or ex vivo graft manipulation were excluded.
Outcomes
Leukemia-free survival (LFS) was the primary endpoint. LFS was defined as
survival without relapse or progression. Relapse incidence (RI) was defined as leu-
kemia recurrence after transplantation; death without relapse or progression was
the competing risk. Overall survival (OS) was defined as death from any cause.
Graft-versus-hostfree, relapse-free survival (GRFS) was defined as the first event
among grade III-IV acute GVHD (aGVHD), severe chronic GVHD (cGVHD), relapse,
and death [8]. Nonrelapse mortality (NRM) was defined as death from any cause
without relapse; relapse was the competing event. Acute grade II-IV and chronic
GVHDwere assigned and graded using standard criteria [9,10].
Statistical Analysis
Median values with respective interquartile ranges (IQR), were used to
express continuous variables while frequencies in percentages were used for
categorical variables. Median follow up was calculated using the reverse of
Kaplan-Meier. OS, LFS, and GRFS were calculated using the Kaplan-Meier esti-
mator. The incidence of aGVHD and cGVHD, RI, and NRM were calculated
using the cumulative incidence estimator to accommodate competing risks
[11]. Competing risks were death for RI, relapse for NRM, relapse or death for
aGvHD and cGVHD. As planned, the impact of baseline variables on outcomes
was evaluated only on patients transplanted in CR1 and CR2. Univariate anal-
yses were done using the log-rank test for LFS, GRFS, and OS and Gray’s test
for cumulative incidence. Multivariate analysis was performed using Cox pro-
portional hazards models for overall and leukemia-free survival, relapse,
NRM, and GRFS only for patients in first and second remission. The variables
included in multivariate models were disease status (CR1 versus CR2), age at
haplo-HCT (0-12 years, versus 13 years and older), stem cell source (PBSC
versus BM) and myeloablative regimen defined as MAC with total body irra-
diation (TBI), MAC-chemotherapy based, and RIC. To take into account the
center effect, we introduced a random effect (also named frailty model) for
each center into the model. The significance level was fixed at.05 and all P
values are 2-sided. All analyses were done using R software version 4.0.0.
RESULTS
Patient, Disease, and Transplant Characteristics
Patient, disease, and transplant characteristics of the 180
patients included in the study are summarized in Table 1.
Median age at transplantation was 9.3 (IQR 6.4-13.7) years.
Disease status at transplant was CR1 in 23.8%, CR2 in 45%, CR3
+ in 12.2%, and active disease in 19%.
Conditioning regimen was RIC in 22.8% of cases (fludara-
bine melphalan in 13 patients and based on low-dose TBI in 21
cases). MAC regimens were mainly based on busulfan (51.7%)
(thiotepa-busulfan and fludarabine in 38 and busulfan and flu-
darabine in 27 cases, respectively), whereas TBI >6 Gy was
used in 25.6% (41 patients).
The GVHD prophylaxis consisted of high-dose PT-Cy, 50 mg/kg
intravenously on days 3 and 4, in combination with other immu-
nosuppressive treatment, as reported in Table 1. Antithymocyte
globulin (ATG) was avoided in most of the cases, being reported in
9.4% of patients (n = 17): 9 received thymoglobulin (Sanofi-Aven-
tis, Paris, France) and 5 received Grafalon (Neovii Biotech, Rappers-
wil, Switzerland), missing information in 3 cases. BMwas themost
frequently used stem cell source (64%, n = 115), and the median
donor age was 37.3 (IQR 28.59-42.79) years.
Hematopoietic Recovery and Acute and Chronic Graft-
Versus-Host Disease
One hundred sixty-three patients achieved neutrophil recov-
ery, within a median time of 19 days (IQR 16-25 days), being
Table 1
Patient and Disease Characteristics
Variables All patients (N = 180) CR1 (N = 43) CR2 (N = 81) CR3 3 (N = 22) Active disease (N = 34)
Age at TX, median [IQR] 9.25 [6.43-13.7] 8.5 [4.2-15.8] 9.4 [6.6-13.1] 11.7 [8-12.7] 8.3 [5-14.9]
Age at transplant
[0-13] 130 (72.22%) 29 (67.44%) 60 (74.07%) 17 (77.27%) 24 (70.59%)
[13-18] 50 (27.78%) 14 (32.56%) 21 (25.93%) 5 (22.73%) 10 (29.41%)
Time between diagnosis and TX
(month), median [IQR]
23.31 [8.59-44.58] 7.1 [5.3-9.1] 28.9 [19.4-44.9] 59 [43.5-83.2] 17 [10.2-33.6]
Year at TX, median (range) 2017 (2011-19) 2017 (2011-19) 2017 (2012-19) 2015 (2012-18) 2015 (2011-19)
Number of TX
First 173 (96.11%) 43 (100%) 77 (95.06%) 20 (90.91%) 33 (97.06%)
Second (one previous auto) 6 (3.33%) 0 (0%) 4 (4.94%) 1 (4.55%) 1 (2.94%)
Third (Two previous auto) 1 (0.56%) 0 (0%) 0 (0%) 1 (4.55%) 0 (0%)
Disease status at transplantation
CR1 43 (23.89%) 43 (100%) 0 (0%) 0 (0%) 0 (0%)
CR2 81 (45%) 0 (0%) 81 (100%) 0 (0%) 0 (0%)
CR3 22 (12.22%) 0 (0%) 0 (0%) 22 (100%) 0 (0%)
Advanced 34 (18.89%) 0 (0%) 0 (0%) 0 (0%) 34 (100%)
All types
B 129 (74.57%) 30 (69.77%) 61 (81.33%) 18 (81.82%) 20 (60.61%)
T 39 (22.54%) 13 (30.23%) 13 (17.33%) 1 (4.55%) 12 (36.36%)
Other 5 (2.89%) 0 (0%) 1 (1.33%) 3 (13.64%) 1 (3.03%)
Missing 7 0 6 0 1
Patient gender
Female 66 (36.67%) 19 (44.19%) 25 (30.86%) 5 (22.73%) 17 (50%)
Male 114 (63.33%) 24 (55.81%) 56 (69.14%) 17 (77.27%) 17 (50%)
Female donor to male recipient
No 132 (73.33%) 32 (74.42%) 61 (75.31%) 12 (54.55%) 27 (79.41%)
Yes 48 (26.67%) 11 (25.58%) 20 (24.69%) 10 (45.45%) 7 (20.59%)
KPS or Lansky
<90 45 (25.71%) 6 (14.63%) 16 (20.25%) 4 (19.05%) 19 (55.88%)
90 130 (74.29%) 35 (85.37%) 63 (79.75%) 17 (80.95%) 15 (44.12%)
Missing 5 2 2 1 0
CMV Donor to Patient
Neg to neg 10 (6.54%) 2 (5.56%) 3 (3.9%) 1 (6.25%) 4 (16.67%)
Neg to pos 13 (8.5%) 4 (11.11%) 5 (6.49%) 0 (0%) 4 (16.67%)
Pos to neg 16 (10.46%) 4 (11.11%) 6 (7.79%) 4 (25%) 2 (8.33%)
Pos to pos 114 (74.51%) 26 (72.22%) 63 (81.82%) 11 (68.75%) 14 (58.33%)
Missing 27 7 4 6 10
Stem cell source
BM 115 (63.89%) 28 (65.12%) 40 (49.38%) 19 (86.36%) 28 (82.35%)
PBSC 65 (36.11%) 15 (34.88%) 41 (50.62%) 3 (13.64%) 6 (17.65%)
In vivo TCD
No 163 (90.56%) 40 (93.02%) 73 (90.12%) 18 (81.82%) 32 (94.12%)
Yes (ATG) 17 (9.44%) 3 (6.98%) 8 (9.88%) 4 (18.18%) 2 (5.88%)
Conditioning regimen
MAC/Chemo 93 (51.67%) 21 (48.84%) 38 (46.91%) 11 (50%) 23 (67.65%)
MAC/TBI 46 (25.56%) 15 (34.88%) 23 (28.4%) 5 (22.73%) 3 (8.82%)
RIC 41 (22.78%) 7 (16.28%) 20 (24.69%) 6 (27.27%) 8 (23.53%)
GVHD prophylaxis
CSA 8 (4.44%) 1 (2.33%) 4 (4.94%) 2 (9.09%) 1 (2.94%)
CSA+MMF 58 (32.22%) 20 (46.51%) 27 (33.3%) 5 (22.73%) 6 (17.65%)
CSA+MMF+TACRO 3 (1.67%) 2 (4.65%) 1 (1.23%) 0 (0%) 0 (0%)
CSA+MTX 6 (3.33%) 3 (6.98%) 2 (2.47%) 0 (0%) 1 (2.94%)
CSA+MTX+MMF 1 (0.56%) 0 (0%) 1 (1.23%) 0 (0%) 0 (0%)
CSA+TACRO 1 (0.56%) 0 (0%) 0 (0%) 1 (4.55%) 0 (0%)
MMF 1 (0.56%) 0 (0%) 0 (0%) 1 (4.55%) 0 (0%)
MMF+SIRO+TACRO 9 (5%) 1 (2.33%) 1 (1.23%) 1 (4.55%) 6 (17.65%)
MMF+TACRO 60 (33.33%) 10 (23.26%) 38 (46.91%) 4 (18.18%) 8 (23.53%)
(continued)
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Table 1 (Continued)
Variables All patients (N = 180) CR1 (N = 43) CR2 (N = 81) CR3 3 (N = 22) Active disease (N = 34)
SIRO 1 (0.56%) 0 (0%) 0 (0%) 0 (0%) 1 (2.94%)
SIRO+TACRO 27 (15%) 4 (9.3%) 5 (6.17%) 8 (36.36%) 10 (29.41%)
TACRO 5 (2.78%) 2 (4.65%) 2 (2.47%) 0 (0%) 1 (2.94%)
TX indicates transplantation; KPS, Karnofski performance status; Neg, negative; Pos, positive; TCD, T-cell depletion; CSA, cyclosporine A; MMF, mycophenolate mofe-
til; TACRO, tacrolimus; MTX, methotrexate; SIRO, sirolimus.
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cumulative incidence of neutrophil engraftment at day 42 and
day 60 was 88.9% (83.2-92.7) and 90% (95% confidence interval
[CI], 84.5-93.6) respectively. The cumulative incidence of 60 days
platelet engraftment was 85.6% (95% CI, 77.7-90.8).
Of the 17 patients who experienced graft failure, the major-
ity were transplanted in active disease status (n = 8), 4 were
CR1, and the remaining 5 were in CR2. At last follow-up, 3
patients were alive, 1 after DLI infusion and 1 after a second
HCT from the same donor, and 14 patients died (3 after receiv-
ing a second HCT from a different donor) at a median of
55 days after haplo-HCT (Supplemental Table S1). No cases of
secondary graft failure were reported.
Cumulative incidence of day 100 grade II-IV and grade III-IV
aGVHD was 28.3% (95% CI, 21.7%-35.2%) and 12.4% (95% CI, 7.9%-
17.8%), respectively. The majority of patients experienced grade II
aGVHD (n = 30), whereas grade III and grade IV aGVHD were
reported in 14 and 9 patients, respectively. Cumulative incidenceFigure 1. (A) Two-year cumulative RI by CR1 and CR2. (B) Two-year cumulative incid
Two-year probability of OS by CR1 and CR2.of 2 years chronic GVHD was 21.9% (95% CI, 16%-29%), and the
extensive involvement was 9.5% (95% CI, 5.3%-15%).
When analyzing the group of patients transplanted in CR1
and CR2, for BM and PBSC recipients cumulative incidence of
grade II-IV acute GVHD was 28.1% (95%CI 17.7-39.5%) and
37.7% (95%CI 24.8-50.6%), P = .14, and cumulative incidence of
grade III-IV aGVHD was 6.2% and 18.9%, P=.04, respectively.
Relapse and Non-Relapse Mortality
Disease recurrence was the most common cause of treat-
ment failure. Cumulative incidence of relapse at 2 years was
25.1%, 37%, and 50.3% for patients in CR1, CR2,and CR3+ and
70.1% for active disease, respectively (Figure 1A).
The overall cumulative incidence of NRM at 2 years was
19.6% (95% CI, 14%-26%) for the whole cohort. In the group of
patients transplanted in CR1 and CR2, NRM was 9.8% and
19.1% for patients in CR1 and CR2, respectively (Table 2,
Figure 1B). Cumulative incidence of NRM was significantlyence NRM by CR1 and CR2. (C) Two-year probability of LFS by CR1 and CR2. (D)
Table 2
Univariate analysis for patients in CR1 and CR2
Variable 2y OS 2y LFS 2y RI 2y NRM 100d AGVH II-IV 2y GRFS 2y CGVH
Disease status
CR1 76.5% [59.5-87.1] 65% [48.1-77.7] 25.1% [12.8-39.5] 9.8% [3.1-21.3] 47.5% [31.3-62.1] 53.6% [37.2-67.5] 33.2% [18.8-48.3]
CR2 61.2% [48.4-71.7] 44% [31.6-55.6] 37% [25.2-48.7] 19.1% [10.9-29] 24.7% [15.7-34.8] 30.9% [20.1-42.4] 21.5% [12.1-32.6]
P value .03 .01 .11 .16 .03 .04 .13
Karnofski performance status
<90 52.1% [26-73] 47.3% [22.6-68.7] 30.3% [10.1-53.7] 22.4% [6.4-44.2] 26.3% [9.2-47.4] 24.7% [8-46] 27.5% [7.2-52.9]
90 69.3% [58.3-77.9] 51.1% [39.9-61.2] 33.7% [23.7-43.9] 15.2% [8.7-23.4] 33% [23.7-42.6] 42.1% [31.4-52.3] 23.2% [14.7-32.9]
P value .27 .67 .99 .53 .98 .27 .73
Patient age
[0-13] 71.6% [60-80.4] 54.4% [42.4-64.8] 30.9% [20.8-41.6] 14.7% [8-23.4] 34.1% [24.2-44.2] 41.9% [30.6-52.9] 28.6% [18.6-39.3]
[13-18[ 54.5% [35.2-70.3] 44.3% [26.1-61] 37.1% [19.8-54.4] 18.6% [7.3-34] 28.1% [13.8-44.4] 33.3% [17.9-49.5] 18.6% [6.4-35.6]
P value .05 .25 .46 .56 .65 .29 .35
Gender
Male 64.2% [51.5-74.4] 47.3% [35-58.7] 36.2% [24.8-47.8] 16.4% [8.9-25.9] 28.8% [18.8-39.4] 36.6% [25.2-48.2] 29.6% [18.8-41.1]
Female 71.3% [53.8-83.1] 59.8% [42.7-73.3] 25.7% [13.1-40.5] 14.5% [5.7-27] 38.6% [24.3-52.8] 44.7% [29-59.2] 19.4% [8.3-33.9]
P value .43 .56 .51 .91 .31 .96 .24
Female-to-male
No 70.7% [59.3-79.4] 55.8% [44.2-65.8] 29.4% [19.7-39.7] 14.9% [8.3-23.2] 35.6% [25.8-45.4] 40.5% [29.8-51] 23.9% [14.9-34.2]
Yes 55.9% [35.3-72.3] 40.3% [21.8-58.1] 41.5% [22.2-59.7] 18.3% [6.4-35] 22.2% [8.8-39.4] 37.1% [19.3-55.1] 31.6% [14.5-50.2]
P value .09 .57 .57 .81 .33 .69 .30
CMV Donor
Neg 61.7% [30.5-82.2] 63.6% [33-83.1] 21.3% [4.7-45.8] 15.2% [2.1-39.7] 35.7% [12.2-60.4] 44.4% [18.9-67.4] 30.3% [8.2-56.5]
Pos 65.4% [54.1-74.5] 47.6% [36.6-57.8] 35.1% [24.9-45.4] 17.3% [10.3-25.8] 30.9% [21.8-40.3] 35.9% [25.8-46] 24% [15.2-34]
P value .86 .33 .41 .74 .49 .84 .59
Regimen
MAC/Chemo 60% [43.8-72.8] 43.6% [29.5-56.9] 38% [24.4-51.6] 18.4% [9.3-29.8] 40% [27-52.7] 25.1% [13.9-38] 22.7% [11.5-36.2]
MAC/TBI 64.1% [45.1-78] 65.3% [46.7-78.8] 17.2% [6.8-31.6] 17.5% [6.9-32.2] 28.6% [14.7-44.1] 54.2% [36.3-69.1] 30.7% [15.7-47.1]
RIC 80.8% [59.8-91.5] 54% [33.4-70.7] 38.3% [19.8-56.6] 7.7% [1.3-22.2] 22.2% [8.8-39.4] 52.3% [31.5-69.5] 25.9% [10.1-45.1]
P value .59 .11 .12 .38 .17 <.01 .55
Stem cell source
BM 77.5% [64.8-86] 57.6% [44.3-68.7] 34.7% [23.1-46.6] 7.8% [2.8-16] 28.1% [17.7-39.5] 48.2% [35.2-60.2] 22.2% [12.5-33.7]
PB 51.1% [35.1-65.1] 43.2% [27.8-57.6] 30.3% [16.9-44.9] 26.5% [14.8-39.9] 37.7% [24.8-50.6] 28.3% [16.1-41.8] 31.8% [18-46.4]
P value .01 .13 .44 <.01 .14 .01 .37
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BM 7.8% (95% CI, 2.8%-16%), P < .001. A total of 86 patients
died: 56 of relapsed disease and 30 of NRM. The most common
cause of NRM was infections (n = 10), followed by GVHD
(n = 8), interstitial pneumonia (n = 3), veno-occlusive disease
(n = 2), and other HSCT-related causes (n = 7).
LFS, GRFS, and OS
Median follow-up duration was 2.7 (95% CI, 2.2-3.2) years.
In the whole group, the probability of 2-year OS, LFS, and GRFS
was 50.8% (95% CI, 42.6%-58.4%), 38.5% (95% CI, 30.8%-46.2%),
and 29.2% (95% CI, 22.2%-36.5%).
The probability of 2-year LFS was 38.5% (95% CI, 30.8%-
46.2%), being 65% (95% CI, 48.1%-77.7%) for patients in CR1,
44% (95% CI, 31.6%-55.6%) for patients in CR2 (Figure 1C), and
18.8% (95% CI, 4.8%-39.8%) for patients in CR3+; 1-year LFS was
3.2% (95% CI, 0.2%-14%) for patients in active disease. The prob-
ability of OS at 2 years was 76.5% for patients in CR1 and 61.2%
for those in CR2 (P = .03) (Figure 1D and Supplemental
Figure S1).
In patients transplanted in CR1 and CR2, according to the
type of conditioning regimen, the 2-year LFS was 65.3% in
recipients of MAC TBI-based, 43.6% in MAC-chemotherapy-
based, and 54% for RIC, respectively (P = .12) (Table 2). The
probability of GRFS at 2 years was 53.6% for patients in CR1
and 30.9% for those in CR2 (P = .04).
Multivariate Analysis for the Patients Transplanted in CR1
and CR2
Multivariate analysis was conducted in patients trans-
planted either in first or second complete remission (Table 3).
Use of PBSC was the only significant factor associated with a
significant increased risk of NRM (HR = 3.13, 95% CI, 1.06-9.18;
P = .04).
Disease status at haplo-HCT was the only independent fac-
tor significantly associated with LFS: CR2 versus CR1
(HR = 2.04, 95% CI, 1.1-3.8; P = .02. Use of TBI-based MAC
(HR = 0.51, 95% CI, 0.28-0.92; P = .03) and RIC (HR = 0.46, 95%
CI, 0.24-0.89; P = .02) was independently associated with
higher GRFS compared to MAC chemotherapy based.
Factors significantly associated with lower OS were CR2
versus CR1 (HR = 2.19, 95% CI, 1.05-4-55; P = .04), age at HCT
older than 13 years (HR = 2.07, 95% CI, 1.1-3.91; P = .04), and
use of PBSC (HR = 1.98, 95% CI, 1.03-3.81; P = .04) (Figure 2).
DISCUSSION
Our study aimed to report outcomes and their risk factors
after Haplo-HCT with PT-Cy in pediatric patients with ALL. To
date, there are very few reports published on the use of Haplo-
HCT for children with ALL and are limited to a few cases. Pub-
lished data report the feasibility of this procedure in children
with malignant disorders [12,13]. Our series on 180 children
with ALL, both receiving MAC and RIC Haplo-HCT showed
favorable outcomes of PT-Cybased GVHD prophylaxis,
namely for patients in disease remission. PT-Cy is effective in
preventing severe GVHD in children with leukemia receiving
unmanipulated HLA-haploidentical transplant, without an
excess of NRM.
Disease status remains the most important prognostic fac-
tor influencing the risk of disease recurrence and the probabil-
ity of LFS and OS. Our study was retrospective and registry
based, and a high proportion of patients underwent transplan-
tation in active disease status and with relapsed ALL, which
usually are associated with poor outcomes [14]. Outcomes of
patients transplanted in CR3+ remain poor because of a high
Figure 2. Two-year probability of OS by stem cell source.
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transplanted in complete remission 1 and 2 were better in
terms of disease recurrence and overall results, highlighting
the importance of early referral to transplant once the indica-
tion is made.
Strategies for obtaining effective disease control before
transplantation and to reduce transplant-related toxicity and
death are desirable to improve results in pediatric patients
with ALL. Importantly, the availability of targeted therapies,
such as anti-CD19 or anti CD22 monoclonal antibodies, and
the CD19-CAR-T cells may dramatically change the results and
the place of HCT in such diseases [15].
On patients in CR1 and CR2, our results confirmed the prog-
nostic impact of age younger than 13 years in overall survival,
although benefits have been reported when the adolescent
population was treated within the pediatric cooperative group
trials [16].
The choice of conditioning regimen should be carefully
evaluated taking into consideration the disease risk, as well
patient-related factors [17]. In our study, the conditioning regi-
men was performed according to transplant center policy, and
it would be possible that among the 41 patients receiving a
reduced-intensity regimen, poor performance status, organ
dysfunction, or other clinical conditions may have impacted
that decision. We should continue to collect data and to
address whether the regimen intensity may influence out-
comes and for which population. Additionally, the duration of
immunosuppression after HCT could be shorter in RIC recipi-
ents to further reduce the risk of disease recurrence and
enhance immune recovery. Comparative trials among RIC and
MAC in patients eligible to receive both treatments are needed
to clearly highlight the place of RIC regimens in childhood ALL.
In the myeloablative setting, recently the results of the
“FORUM” prospective randomized trial [18] showed the
advantage of the use of TBI-based myeloablative regimens
with significant reduction in relapse risk in patients with ALL
older than 4 years of age. In our study, when analyzing the
patients in CR1 and CR2, the use of a TBI-based MAC regimen
was associated with a significantly higher GRFS.
Another important strategy for preventing relapse is the
use of post-transplantation target drugs or adoptive immuno-
therapy [19] that could be performed in a timely manner in
the haploidentical HCT setting, because family donors can be
rapidly available for subsequent donation when needed [20].
A low incidence of acute GVHD has been reported [7,21] in
the setting of unmanipulated haplo-HCT. Of note in our series,9.6% of patients, namely recipients of PBSC, received the com-
bination of PT-Cy with ATG. One may argue that this strategy
has been adopted to decrease the risk of GVHD in the setting
of HLA-mismatched HCT, especially in the pediatric popula-
tion. Furthermore, the action of PT-Cy in preventing GVHD
after BM graft has been recently described, not only based on
the selective induction of tolerance and intrathymic clonal
deletion of allo-reactive T lymphocytes, but also through spe-
cific effects on T-cell subsets such as T-regs [22].
In the group of patients transplanted in CR1 and CR2, the
use of PBSC as a stem cell source was associated with signifi-
cantly lower OS and higher NRM. This is an important finding
because the graft cell source is a modifiable factor, meaning
that clinicians can make the option to choose bone marrow as
the preferred graft source according to patient and disease
characteristics. Our results are different from findings reported
in the adults [21]; however, we acknowledge that our series is
not comparable, reporting only children receiving MAC regi-
men in the majority of cases. More focused comparisons of
graft sources taking into account differences among children
and adults are warranted. We were not able to detect statisti-
cally significant differences in GVHD according to the stem cell
source, despite the higher incidence in PBSC recipients. The
lack of difference could be related to the low number of GVHD
events found in our series; however, the toxicity and morbid-
ity related to the GVHD ultimately may have an impact in the
NRM and OS. Low incidence of chronic GVHD has been
reported by a single-center study with the use of G-
CSFprimed unmanipulated BM together with harvested
PBSC from haploidentical donor with PT-Cy; however, larger
number are needed to clearly highlight the possible effect of
the combination of the stem cell source [23]. We are aware of
the limitations of our study given its retrospective nature.
Therefore we should have caution for any conclusion for the
analysis of relapse because of the lack of minimal residual dis-
ease status before HCT. Also the burden of post-HCT long-
term complications should be carefully considered, especially
in the pediatric setting to avoid quality-of-life impairment
[24].
Also, we were unable to collect data on infectious complica-
tions and immune reconstitution to evaluate the efficacy of PT-
Cy in the naïve and memory T-cell compartment, which is
important also to address the relative benefit of PT-Cybased
approaches over the T-cell a/bdepleted strategy.
Curiously, despite the impact of donor kinship being associ-
ated with a decreased risk of relapse, when the mother was the
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strated [25] in the setting of haplo-HCT using PT-Cy.
In summary we have confirmed the dismal prognosis of
patients transplanted in active disease and CR3+. For patients
transplanted in CR1 and CR2, our results show the feasibility of
Haplo-HCT with PT-Cy in children with ALL [6], and impor-
tantly we have described outcomes and their risk factors after
this strategy in the largest series described so far. The use of
BM cells as a graft source and remission status of ALL at trans-
plantation are the most important factors associated with
main outcomes. How the PT-Cy strategy might compare with
the results of the new techniques in the T-cell depleted haploi-
dentical setting, such as the selective depletion of the a/b T-
and B-cells [2], or of unrelated donors HCT, needs to be care-
fully evaluated, also taking into account the cost-effectiveness
of the strategies and the patients’ quality of life.
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